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Abstract
The scope of application EFSA-GMO-DE-2016-133 is for food and feed uses, import and processing of
genetically modiﬁed (GM) maize MZHG0JG in the European Union. Maize MZHG0JG was developed to
confer tolerance to the herbicidal active substances glyphosate and glufosinate-ammonium. The
molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed
safety assessment. None of the identiﬁed differences in the agronomic/phenotypic and compositional
characteristics tested between maize MZHG0JG and its conventional counterpart needs further
assessment, except for early stand count (pre-thinning). The GMO Panel does not identify safety
concerns regarding the toxicity and allergenicity of the mEPSPS and PAT proteins as expressed in
maize MZHG0JG, and ﬁnds no evidence that the genetic modiﬁcation would change the overall
allergenicity of maize MZHG0JG. The nutritional impact of food/feed derived from maize MZHG0JG is
expected to be the same as that of food/feed derived from the conventional counterpart and
commercial non-GM maize reference varieties. The GMO Panel concludes that maize MZHG0JG is
nutritionally equivalent to and as safe as the conventional counterpart and non-GM maize reference
varieties tested, and no post-market monitoring of food/feed is considered necessary. In the case of
accidental release of viable maize MZHG0JG grains into the environment, maize MZHG0JG would not
raise environmental safety concerns. The post-market environmental monitoring plan and reporting
intervals are in line with the intended uses of maize MZHG0JG. In conclusion, the GMO Panel considers
that maize MZHG0JG, as described in this application, is as safe as its conventional counterpart and
the tested non-GM maize reference varieties with respect to potential effects on human and animal
health and the environment.
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Summary
In the present scientiﬁc opinion, the scientiﬁc Panel on Genetically Modiﬁed Organisms of the
European Food Safety Authority (hereafter referred to as the ‘GMO Panel’) reports the outcome of its
risk assessment of maize MZHG0JG in the context of its scope as deﬁned in application EFSA-GMO-DE-
2016-133.1 The GMO Panel conducted the assessment of maize MZHG0JG in line with the principles
described in Regulation (EU) No 503/2013 and its applicable guidelines for the risk assessment of
genetically modiﬁed (GM) plants.
The molecular characterisation data establish that maize MZHG0JG contains a single insert
consisting of one copy of the mepsps and pat expression cassettes. Bioinformatics analyses of the
sequences encoding the newly expressed proteins and other open reading frames present within the
insert or spanning the junctions between the insert and genomic DNA do not indicate signiﬁcant
similarities to toxins and allergens. The stability of the inserted DNA and introduced trait is conﬁrmed
over several generations. The methodology used to quantify the levels of the mEPSPS and PAT
proteins is considered adequate. The protein characterisation data comparing the structural,
biochemical and functional properties of plant- and microbe-derived mEPSPS and PAT proteins indicate
that these proteins are equivalent, and the microbe-derived protein can be used in safety studies.
None of the identiﬁed differences in the agronomic/phenotypic and compositional characteristics
tested between maize MZHG0JG and its conventional counterpart needs further assessment, with the
exception of early stand count (pre-thinning) whose environmental impact is assessed.
The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the
mEPSPS and PAT proteins as expressed in maize MZHG0JG, and ﬁnds no evidence that the genetic
modiﬁcation would change the overall allergenicity of maize MZHG0JG. The nutritional impact of food/
feed derived from maize MZHG0JG is expected to be the same as that of food/feed derived from the
conventional counterpart and commercial non-GM maize reference varieties. The GMO Panel concludes
that maize MZHG0JG is nutritionally equivalent to and as safe as the conventional counterpart and
non-GM maize reference varieties tested, and no post-market monitoring of food/feed is considered
necessary.
Considering the introduced trait, the outcome of the comparative analysis, and the routes and
levels of exposure, the GMO Panel concludes that maize MZHG0JG would not raise safety concerns in
the case of accidental release of viable GM maize grains into the environment. The post-market
environmental monitoring plan and reporting intervals are in line with the intended uses of maize
MZHG0JG.
Based on the relevant publications identiﬁed through the literature searches, the GMO Panel does
not identify any safety issues pertaining to the intended uses of maize MZHG0JG. In the context of
post-market environmental monitoring, the applicant should improve future literature searches
according to the GMO Panel recommendations given in this scientiﬁc opinion.
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-DE-
2016-133, additional information provided by the applicant, scientiﬁc comments submitted by the
Member States and relevant scientiﬁc publications. The GMO Panel concludes that maize MZHG0JG,
as described in this application, is as safe as its conventional counterpart and the tested non-GM
maize reference varieties with respect to potential effects on human and animal health and the
environment.
1 The scope of the application EFSA-GMO-DE-2016-133 is for food and feed uses, import and processing of maize MZHG0JG
within the European Union (EU).
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1. Introduction
The scope of application EFSA-GMO-DE-2016-133 is for food and feed uses, import and processing
of the genetically modiﬁed (GM) herbicide-tolerant maize MZHG0JG in the European Union (EU).
1.1. Background
On 27 September 2016, the European Food Safety Authority (EFSA) received from the Competent
Authority of Germany application EFSA-GMO-DE-2016-133 for authorisation of maize MZHG0JG
(Unique Identiﬁer SYN-∅∅∅JG-2), submitted by Syngenta (hereafter referred to as ‘the applicant’)
according to Regulation (EC) No 1829/2003.2
Following receipt of application EFSA-GMO-DE-2016-133, EFSA informed EU Member States and the
European Commission, and made the application available to them. Simultaneously, EFSA published
the summary of the application.3
EFSA checked the application for compliance with the relevant requirements of Regulation (EC)
No 1829/2003 and Regulation (EU) No 503/20134, and, when needed, asked the applicant to
supplement the initial application. On 10 January 2017, EFSA declared the application valid.
From validity date, EFSA and its scientiﬁc Panel on Genetically Modiﬁed Organisms (hereafter
referred to as the ‘GMO Panel’) endeavoured to respect a time limit of six months to issue a scientiﬁc
opinion on application EFSA-GMO-DE-2016-133. Such time limit was extended whenever EFSA and/or
its GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment
was made available to the Member States and European Commission (for further details, see
Section ‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of the Member States, including national Competent Authorities within the meaning of
Directive 2001/18/EC.5 Member States had three months to make their opinion known on application
EFSA-GMO-DE-2016-133 as of date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientiﬁc risk assessment of maize MZHG0JG in the context of its scope as
deﬁned in application EFSA-GMO-DE-2016-133.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation, and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
In addition to the present scientiﬁc opinion, EFSA was also asked to report on the particulars listed
under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003, but not to give an opinion on them,
because they pertain to risk management.6
2. Data and methodologies
2.1. Data
The GMO Panel based its scientiﬁc risk assessment of maize MZHG0JG on the valid application
EFSA-GMO-DE-2016-133, additional information provided by the applicant during the risk assessment,
relevant scientiﬁc comments submitted by the Member States and relevant peer-reviewed scientiﬁc
publications.
2 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
3 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2016-00583.
4 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modiﬁed food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.
5 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
6 These particulars can be found in the technical report by EFSA on application EFSA-GMO-DE-2016-133, made available in the
EFSA Register of Questions.
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2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU)
No 503/2013, its applicable guidelines (i.e. EFSA GMO Panel, 2010a,b, 2011a,b, 2015) and explanatory
notes (i.e. EFSA, 2014, 2017a,b) for the risk assessment of GM plants.
For the assessment of 90-day animal feeding studies, the GMO Panel took into account the criteria
included in the 2011 EFSA Scientiﬁc Committee guidance on conducting repeated-dose 90-day oral
toxicity study in rodents on whole food/feed and the explanatory statement for its applicability (EFSA,
2014).
The GMO Panel also assessed the applicant’s literature searches, which include a scoping review, in
accordance with the recommendations on literature searching outlined in EFSA (2010, 2017a).
In the frame of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatic and statistical analyses, respectively.
3. Assessment
3.1. Systematic literature review7
The GMO Panel assessed the applicant’s literature searches on maize MZHG0JG, which included a
scoping review, according to the guidelines given in EFSA (2010, 2017a).
A systematic review as referred to in Regulation (EU) No 503/2013 has not been provided in
support to the risk assessment of application EFSA-GMO-DE-2016-133. Based on the outcome of the
scoping review, the GMO Panel agrees that there is limited value of undertaking a systematic review
for maize MZHG0JG at present.
Although the overall quality of the performed literature searches is acceptable, the GMO
Panel considers that future searches on maize MZHG0JG should be improved. The GMO Panel therefore
recommends the applicant to:
• Ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientiﬁc terminology, common typos, translation issues);
• Use controlled vocabulary (subject indexing) in the electronic bibliographic databases where it
is available, and, where subject headings are available, use both free-text terms and controlled
vocabulary in the searches;
• Include intended trait-speciﬁc search terms;
• Assess the relevance and risk assessment implications of publications retrieved via searches
beyond electronic bibliographic databases.
Based on the relevant publications identiﬁed through the literature searches, the GMO Panel does
not identify any safety issues pertaining to the intended uses of maize MZHG0JG.
3.2. Molecular characterisation8
3.2.1. Transformation process and vector constructs
Maize MZHG0JG was developed by Agrobacterium tumefaciens (also known as Rhizobium
radiobacter)-mediated transformation. Immature embryos of maize (Zea mays) line NP2222 were co-
cultured with a disarmed A. tumefaciens strain ABI containing the vector pSYN18857. The plasmid
pSYN18857 used for the transformation contains two expression cassettes between the right and left
borders of the T-DNA, containing the following genetic elements:
• The mepsps expression cassette consists of the e35S promoter from Cauliﬂower mosaic virus
(CaMV), the Ubi158 maize ubiquitin constitutive promoter, the chloroplast transit peptide (CTP)
based on CTP sequences from Heliathus annuus and Z. mays, the mutated epsps from
Z. mays that confers tolerance the herbicidal active substance glyphosate, and the terminator
from the maize ubiquitin (ZMU29158-3) gene;
7 Dossier: Part II – Section 7; Additional information: 28/5/2018, 16/7/2018 and 17/7/2018.
8 Dossier: Part II – Sections 1.2, 1.2.2.3, 1.4.1–1.4.7 and 7; Additional information: 3/11/2017 and 15/5/2018.
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• The pat expression cassette consists of the 35S promoter from CaMV, the codon-optimized
version of the pat gene from Streptomyces viridochromogenes strain T€u494 that confers
tolerance the herbicidal active substance glufosinate-ammonium, and the terminator sequence
from the A. tumefaciens nos gene.
The vector backbone contains elements necessary for the maintenance of the plasmid in bacteria.
3.2.2. Transgene constructs in the GM plant
Molecular characterisation of maize MZHG0JG was performed by Southern analysis, polymerase
chain reaction (PCR) and DNA sequence analysis, in order to determine insert copy number, size and
organisation of the inserted sequences, and conﬁrm the absence of plasmid backbone sequences. The
approach used is acceptable both in terms of coverage and sensitivity.
Southern analyses indicate that maize event MZHG0JG contains a single insert, which consists of a
single copy of the T-DNA in the same conﬁguration as in the pSYN18857 transformation vector. The
insert and copy number are conﬁrmed by multiple restriction enzyme/probe combinations covering the
T-DNA region and ﬂanking regions. PCR analyses conﬁrm the results obtained by the Southern
analyses. The absence of vector backbone sequences is demonstrated by Southern analysis using
backbone-speciﬁc overlapping probes.
The nucleotide sequence of the entire insert of maize MZHG0JG together with 1,000 bp of the 50
and 1,000 bp of the 30 ﬂanking regions were determined. The insert of 8,910 bp is identical to the
T-DNA of pSYN18857, except for the truncation of the right and left borders, and the insertion of 4 bp
at the 50 end of the MZHG0JG insert and 39 bp at the 30 end of the insert.
A comparison with the pre-insertion locus indicates that 22 bp are deleted from the maize genomic
DNA. The possible interruption of known endogenous maize genes by the insertion in maize MZHG0JG
was evaluated by bioinformatics analyses of the pre-insertion locus and the genomic sequences
ﬂanking the insert. The results of these analyses do not reveal the interruption of any known
endogenous gene in maize MZHG0JG.
The results of segregation (see Section 3.2.5) and bioinformatics analyses establish that the insert
is located in the nuclear genome.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed mEPSPS and
PAT proteins reveal no signiﬁcant similarities to known toxins and allergens. In addition, updated
bioinformatics analyses of the newly created open reading frames (ORFs) within the insert or spanning
the junctions between the insert and genomic DNA indicate that the expression of an ORF showing
signiﬁcant similarities to toxins or allergens is highly unlikely. To assess the possibility for horizontal
gene transfer (HGT) by homologous recombination (HR), the applicant performed a sequence identity
analysis of the regions of bacterial origin in maize MZHG0JG. The likelihood and potential
consequences of plant-to-microorganisms gene transfer are described in Section 3.5.1.2.
3.2.3. Protein characterisation and equivalence
Maize MZHG0JG expresses two new proteins, mEPSPS and PAT. Given the technical restraints in
producing large enough quantities from plants, these proteins were recombinantly produced in
Escherichia coli. A set of biochemical methods was employed to demonstrate the equivalence between
the maize- and E. coli-derived mEPSPS and PAT proteins. Puriﬁed proteins from these two sources were
characterised and compared in terms of their physicochemical, structural and functional properties.
3.2.3.1. mEPSPS characterisation and equivalence
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis
show that plant- and microbe-derived mEPSPS proteins have the expected molecular weight of
~47.4 kDa and are comparably immunoreactive to mEPSPS protein speciﬁc antibodies. Glycosylation
detection analysis demonstrates that none of the mEPSPS proteins are glycosylated. Amino acid
sequence analysis of the plant-derived mEPSPS protein by mass spectrometry (MS) methods shows
that the protein matches the deduced sequence as deﬁned by the mepsps gene. These sequence
analysis data are consistent with the previously analysed microbe-derived mEPSPS protein. In addition,
the MS data show that the N-terminal methionine is truncated. Such a modiﬁcation is common in
eukaryotic proteins (e.g. Moerschell et al., 1990). Functional equivalence is demonstrated by a
biochemical in vitro activity assay which shows that plant- and microbe-derived mEPSPS proteins have
comparable activity.
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3.2.3.2. PAT characterisation and equivalence
SDS-PAGE and western blot analysis show that both plant- and microbe-derived PAT proteins have
the expected molecular weight of ~ 20.5 kDa and are comparably immunoreactive to PAT protein speciﬁc
antibodies. Glycosylation detection analysis demonstrated that none of the PAT proteins are glycosylated.
Amino acid sequence analysis by MS methods shows that both PAT proteins match the deduced
sequence as deﬁned by the pat gene. Functional equivalence was demonstrated by a biochemical in vitro
activity assay which shows that plant- and microbe-derived PAT proteins have comparable activity.
The protein characterisation data comparing the structural, biochemical and functional properties of
plant- and microbe-derived mEPSPS and PAT proteins, indicate that these proteins are equivalent.
Therefore, the GMO Panel accepts the use of the mEPSPS and PAT proteins produced in bacteria for
safety studies.
3.2.4. Information on the expression of the insert
Protein levels of mEPSPS and PAT were analysed by enzyme-linked immunosorbent assay (ELISA) in
material harvested from a ﬁeld trial across four locations in the USA during the 2013 growing season.
Samples analysed included leaves (V6, R1, R6 and senescence), root (V6, R1, R6 and senescence),
whole plant (V6, R1 and R6), pollen (R1) and grains (R6 and senescence) from plants both treated
and non-treated with glyphosate- and glufosinate-ammonium-containing herbicides. The mean values,
standard deviations and ranges of protein expression levels in grains (R6, n = 20) and leaves (R1,
n = 20) of the mEPSPS and PAT proteins are summarised in Table 1.
3.2.5. Inheritance and stability of inserted DNA
Genetic stability of maize MZHG0JG insert was assessed by Southern analysis of genomic DNA from
ﬁve consecutive generations and segregation analysis of both herbicide tolerance traits in maize
MZHG0JG. For the Southern analysis, the restriction enzyme/probe combinations used were sufﬁcient
to conclude that all the plants tested retain the single copy of the insert and ﬂanking regions, which
were stably inherited in subsequent generations. The results support the presence of a single insertion,
segregating in a Mendelian fashion.
3.2.6. Conclusion on molecular characterisation
The molecular characterisation data establish that maize MZHG0JG contains a single insert
consisting of one copy of the mepsps and pat expression cassettes. Bioinformatics analyses of the
sequences encoding the newly expressed proteins and other ORFs present within the insert or
spanning the junctions between the insert and genomic DNA indicate that the expression of an ORF
showing signiﬁcant similarities to toxins or allergens is highly unlikely. The stability of the inserted DNA
and introduced trait is conﬁrmed over several generations. The methodology used to quantify the
levels of the mEPSPS and PAT proteins is considered adequate. The protein characterisation data
Table 1: Means, standard deviations and ranges of protein levels in grains (n = 20) and leaves
(n = 20) (lg/g dry weight) in maize MZHG0JG
Tissue
Glyphosate/Glufosinate-ammonium treatment
Untreated Treated
Grains (R6)
mEPSPS
58.23(a)  14.87(b)
(30.37–86.15)(c)
61.14  15.49
(34.82–93.06)
PAT < LOD–0.04 < LOD–0.04
Leaves (R1)
mEPSPS
1,934  678
(920–3,203)
1,816  856
(940–3,507)
PAT
9.95  3.02
(6.21–17.03)
10.22  3.37
(6.75–16.87)
LOD: limit of detection.
(a): Mean value.
(b): Standard deviation.
(c): Range.
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comparing the structural, biochemical and functional properties of plant- and microbe-derived mEPSPS
and PAT proteins indicate that these proteins are equivalent, and the microbe-derived protein can be
used in safety studies.
3.3. Comparative analysis9
3.3.1. Overview of studies conducted for the comparative analysis
Application EFSA-GMO-DE-2016-133 presents data on agronomic/phenotypic characteristics, as well
as forage and grain composition, of maize MZHG0JG derived from ﬁeld trials performed at eight sites
in the USA in 2013. In addition, the application contains data on characteristics of seed from maize
MZHG0JG (Table 2).10
3.3.2. Experimental ﬁeld trial design and statistical analysis
At each ﬁeld trial site, the following materials were grown: maize MZHG0JG, the conventional
counterpart maize NP2222 9 NP2391 and six commercial non-GM maize reference varieties, all treated
with conventional herbicides management regimes; and maize MZHG0JG exposed to the intended
glyphosate- and glufosinate-ammonium-containing herbicides, in addition to the conventional herbicides.
The agronomic/phenotypic and compositional data were analysed as speciﬁed by EFSA GMO
Panel (2010b, 2011a,b). This includes, for each of the two treatments of maize MZHG0JG, the application
of a difference test (between the GM maize and its conventional counterpart) and an equivalence test
(between the GM maize and the set of non-GM maize reference varieties).11 The results of the
equivalence test are categorised into four possible outcomes (I–IV, ranging from equivalence to
non-equivalence).
3.3.3. Suitability of selected test materials
3.3.3.1. Selection of the GM maize line and comparator
Maize MZHG0JG was obtained through the transformation of the inbred line NP2222. This GM
inbred line was then crossed with the inbred line NP2391 to produce the maize MZHG0JG hybrid used
in the comparative analysis.
The comparator used in the ﬁeld trials is the non-GM maize hybrid NP2391 9 NP2222, which has
the same genetic background as maize MZHG0JG (as documented by the pedigree), and is therefore
considered to be the appropriate conventional counterpart.
Table 2: Main comparative analysis studies to characterise maize MZHG0JG provided in application
EFSA-GMO-DE-2016-133
Study focus Study details Comparator
Commercial non-GM maize
reference varieties
Agronomic and
phenotypic analysis
Field study, USA, 2013, 8 sites
(a)
NP2222 9 NP2391 6
(b)
Compositional
analysis
Seed germination
F1 grains tested under controlled
conditions NP2222 9 NP2391 3
(c)
GM: genetically modiﬁed.
(a): The ﬁeld trials were located in Richland, IA; York, NE; Seymour, IL; Bagley, IA; Larned, KS; Stewardson, IL; Wyoming, IL;
and Germansville, PA. Additional sites were present in Carlyle, IL and Delavan, WI and were excluded from the statistical
analysis due to unfavourable weather conditions (see additional information 24/10/2017 and 15/2/2018).
(b): The commercial non-GM maize reference varieties used in the 2013 ﬁeld trials are the hybrids: H-7191, H-7540, SY
GENEROSO, NK LUCIUS, CISKO and SY PROVIAL.
(c): The commercial non-GM maize reference varieties used in the seed germination study are the hybrids: NK OCTET, NK
LUCIUS and CISKO.
9 Dossier: Part II – Section 1.3 and 7; Additional information: 24/10/2017, 15/2/2018 and 14/5/2018.
10 A study on pollen germination is also provided, and is discussed in Section 3.3.5.2.
11 The purpose of the test of equivalence is to evaluate the estimated mean values for maize MZHG0JG taking into account
natural variability as deﬁned by a set of commercial non-GM maize reference varieties with a history of safe use for
consumption as food or feed.
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Maize MZHG0JG and its conventional counterpart have a comparative relative maturity (CRM) ranging
between 105 and 107, and are suitable for growing in a range of environments across North America.
3.3.3.2. Selection of commercial non-GM maize reference varieties
Six commercial non-GM maize reference varieties with a CRM ranging from 93 to 115 were grown
at each ﬁeld trial site (see Table 2). Based on the information on the relative maturity classes, the
GMO Panel considers that the selected non-GM maize reference varieties are appropriate for the
comparative analysis.
3.3.3.3. Seed production and quality
Seeds of maize MZHG0JG and its conventional counterpart used in the ﬁeld trials (see Table 2)
were produced, harvested and stored under similar conditions. The genetic purity of maize MZHG0JG
seed lots was conﬁrmed via event-speciﬁc real-time PCR analysis.
The applicant tested the germination rate of seeds harvested from maize MZHG0JG (F1 seeds), the
conventional counterpart and three non-GM maize varieties.12 Germination was tested in growth
chambers under controlled conditions at six different temperature regimes. The endpoints analysed
were the numbers of normal germinated seeds, abnormal germinated seeds, dead seeds, and dormant
and hard seeds.
A statistically signiﬁcant reduction in germination rate is observed between maize MZHG0JG and its
conventional counterpart at two of the six different temperature regimes (i.e. constant 25°C regime
and the alternating 20°C/30°C regime), but these differences are considered of small magnitude (less
than 3%).
The test materials used in the seed germination study derive from seed lots other than the one
used for the ﬁeld trials. Therefore, the GMO Panel considers that the study does not allow drawing
conclusions on the speciﬁc germinability of the test materials used for the comparative analysis, but
only on possible unintended effects due to the presence of event MZHG0JG.
Although the applicant refers to seed dormancy when discussing the generated data on seed
characteristics of maize MZHG0JG, no data on induced seed dormancy were supplied.
3.3.3.4. Conclusion on suitability
The GMO Panel is of the opinion that the maize MZHG0JG hybrid, its conventional counterpart and
non-GM maize reference varieties were properly selected, and are of sufﬁcient quality. Therefore, the
test materials are considered suitable for the comparative analysis.
3.3.4. Representativeness of the receiving environments
3.3.4.1. Selection of ﬁeld trial sites
The eight sites selected for the ﬁeld trials were located in commercial maize-growing regions of North
America. Soil types of the selected sites were diverse,13 corresponding to optimal and near-optimal
conditions for the cultivation of maize (Sys et al., 1993). The GMO Panel considers that the selected sites
reﬂect commercial maize-growing regions in which the test materials are likely to be grown.
3.3.4.2. Meteorological conditions
Maximum and minimum mean temperatures and sum of precipitations were provided on a monthly
basis. No exceptional weather conditions were reported at any of the selected ﬁeld trial sites. The
GMO Panel considers that the meteorological dataset falls within the range of climatic conditions
normally occurring at these sites.
3.3.4.3. Management practices
The ﬁeld trials conducted, included plots containing maize MZHG0JG exposed to the intended
herbicides (glyphosate and glufosinate-ammonium) in addition to the conventional herbicides, plots
with the conventional counterpart treated with conventional herbicides, and plots with maize MZHG0JG
treated with the same conventional herbicides. Glufosinate-ammonium-containing herbicides were
applied at the V3–V4 growth stage and glyphosate-containing herbicides at the V5–V6 growth stage.
12 Test materials were collected from three sites of the 2012 ﬁeld trials: Story, Iowa (IALL); Warren, Illinois (ILMN); and Lehigh,
Pennsylvania (PAGR).
13 Soil types of the ﬁeld trials were silty clay loam, clay loam, loam and silt loam.
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At some ﬁeld trial sites, planting was done later than usual, resulting in a shorter growing cycle.
The additional information indicated that the shorter growing cycle was unlikely to affect the
agronomic/phenotypic and compositional data. In addition, thinning was applied to achieve a more
homogeneous plant density across plots.
3.3.4.4. Conclusion on representativeness
The GMO Panel concludes that the geographical locations, soil characteristics, meteorological
conditions of the ﬁeld trial sites and most of the management practices applied are typical for
receiving environments where the tested materials could be grown.
3.3.5. Agronomic and phenotypic analysis
3.3.5.1. Agronomic and phenotypic characteristics tested under ﬁeld conditions
Ten agronomic/phenotypic endpoints14 as well as information on abiotic stressors, disease incidence
and insect damage were collected from all ﬁeld trial sites (see Table 2). Two endpoints (early stand
count post-thinning and total lodging) were not subjected to a formal statistical analysis
(Section 3.3.2) because they did not fulﬁl the assumptions of analysis of variance.
The test of difference and the test of equivalence were applied to eight endpoints, with the
following results:
• For maize MZHG0JG (treated with conventional herbicides), the test of difference identiﬁed
statistically signiﬁcant differences for early stand count (pre-thinning) and yield. Yield fell under
equivalence category I, while early stand count (pre-thinning) fell under category IV;15
• For maize MZHG0JG (treated with the intended herbicides), the test of difference identiﬁed a
statistically signiﬁcant difference for plant height, which fell under the equivalence category II.
Early stand count (pre-thinning) for the GM maize fell under equivalence category IV, but was
not signiﬁcantly different from the conventional counterpart.15
For early stand count (pre-thinning), the lack of equivalence observed for both treatments could
indicate a different establishment of maize MZHG0JG compared to non-GM maize reference varieties.
The applicant thinned the plots in order to remove the differences in early stand count (pre-thinning)
between maize MZHG0JG, the conventional counterpart and non-GM maize reference varieties. As no
further impact on the subsequent crop development endpoints was observed, the GMO
Panel considers that the comparative analysis was not affected by this possible differential
establishment.
Whether the difference in early stand count (pre-thinning) that fell under category IV can lead to
an environmental adverse effect is considered in Section 3.5.1.1.
3.3.5.2. Agronomic and phenotypic characteristics tested under controlled conditions
The applicant reports data on pollen grain diameter and the results of Lugol staining of pollen of
maize MZHG0JG, its conventional counterpart and three commercial non-GM maize reference hybrids16
grown under ﬁeld conditions in the USA.17 No signiﬁcant differences between maize MZHG0JG and its
conventional counterpart are observed in pollen diameter and stain uptake the latter being used to
measure pollen viability.
3.3.6. Compositional analysis
Maize MZHG0JG grains and forage harvested from the ﬁeld trials in the USA in 2013 (Table 2) were
analysed for 82 constituents (9 in forage and 73 in grain), including the key constituents
recommended by OECD (2002). The statistical analysis was not applied to 15 grain constituents,18
14 Early stand count (pre-thinning), early stand count (post-thinning), ﬁnal stand count, days to 50% pollen shed, days to 50%
silking, total lodging, plant height, grain moisture, test weight and yield.
15 The estimated mean values for early stand count pre-thinning (plants/m2) were: 7.32 for maize MZHG0JG (treated with
conventional herbicides); 7.43 for maize MZHG0JG (treated with the intended herbicides); and 7.54 for the conventional
counterpart. The equivalence limits were (7.79, 8.29).
16 Non-GM maize hybrids were: NK OCTET, NK LUCIUS and CISKO.
17 The ﬁeld trial site was located in Mebane, NC.
18 Caprylic acid (8:0), capric acid (10:0), lauric acid (12:0), myristic acid (14:0), myristoleic acid (14:1), pentadecanoic acid
(15:0), pentadecenoic acid (15:1), heptadecenoic acid (17:1), c-linolenic acid (18:3), eicosadienoic acid (20:2), eicosatrienoic
acid (20:3), arachidonic acid (20:4), sodium, selenium and furfural.
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because more than half of the observations were below the limit of quantiﬁcation (LOQ), and to
moisture levels in grain, as the grains were dried before the analytical measurements.
The statistical analysis was applied to the remaining 66 constituents (9 in forage19 and 57 in grain20);
a summary of the outcome of the test of difference and the test of equivalence is presented in Table 3:
• For maize MZHG0JG (treated with conventional herbicides), signiﬁcant differences with the
conventional counterpart were identiﬁed for 29 endpoints (26 in grain and 3 in forage), which
all fell under equivalence category I or II. Among the 37 endpoints for which no signiﬁcant
difference was observed, acid detergent ﬁbre and ferulic acid fell under equivalence
category III/IV.
• For maize MZHG0JG (treated with the intended herbicides), signiﬁcant differences with the
conventional counterpart were identiﬁed for 34 endpoints (31 in grain and 3 in forage), which
all fell under equivalence category I or II. Among the 32 endpoints for which no signiﬁcant
difference was observed, ferulic acid in grain fell under equivalence category IV.
The GMO Panel assessed all signiﬁcant differences between maize MZHG0JG and its conventional
counterpart, taking into account the potential impact on plant metabolism and the natural variability
observed for the set of commercial non-GM maize reference varieties. No endpoints showing signiﬁcant
differences between maize MZHG0JG and its conventional counterpart and falling under category III/
IV have been identiﬁed.
3.3.7. Conclusion on comparative analysis
The GMO Panel concludes that, except for early stand count (pre-thinning), none of the differences
identiﬁed in the agronomic/phenotypic characteristics tested between maize MZHG0JG and its
conventional counterpart needs further assessment. The identiﬁed difference for early stand count
(pre-thinning) and its potential environmental impact are discussed in Section 3.5.1.1.
Table 3: Outcome of the comparative compositional analysis in grains and forage for maize
MZHG0JG. The table shows the number of endpoints in each category
Test of difference(a)
Not treated(c) Treated(c)
Not
different
Signiﬁcantly
different
Not
different
Signiﬁcantly
different
Test of
equivalence(b)
Category I/II 35 29(d) 31 34(d)
Category III/IV 2(e) – 1(e) –
Total endpoints 66 66
(a): Comparison between maize MZHG0JG and its conventional counterpart.
(b): Four different outcomes: Category I (indicating full equivalence to non-GM maize reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
(c): Not treated/treated with the intended glyphosate- and glufosinate-ammonium-containing herbicides.
(d): Endpoints with signiﬁcant differences between maize MZHG0JG and its conventional counterpart falling under equivalence
category I–II (treated and non-treated).
For grain, both treated and untreated: carbohydrates, NDF, copper, iron, b-carotene, pyridoxine, a-tocopherol, alanine,
arginine, aspartic acid, glutamic acid, histidine, isoleucine, leucine, phenylalanine, proline, serine, threonine, tryptophan,
valine, heptadecanoic acid (17:0) and p-coumaric acid; only treated: protein, thiamine, cystine, lysine, methionine, palmitic
acid (16:0), linolenic acid (18:3), behenic acid (22:0) and inositol; only untreated: potassium, niacin, folic acid and phytic acid.
For forage, both treated and untreated: protein and carbohydrates; only treated: calcium; only untreated: phosphorus.
(e): Endpoints in grain with no signiﬁcant differences between maize MZHG0JG and its conventional counterpart and falling
under equivalence category III–IV: ferulic acid (both treated and untreated) and ADF (only untreated).
19 Moisture, protein, fat, ash, carbohydrates, acid detergent ﬁbre (ADF), neutral detergent ﬁbre (NDF), calcium and phosphorus.
20 Proximates and ﬁbre content (protein, fat, ash, carbohydrates, acid detergent ﬁbre (ADF), neutral detergent ﬁbre (NDF) and
total dietary ﬁbre (TDF)), starch, minerals (calcium, copper, iron, magnesium, manganese, phosphorus, potassium and zinc),
vitamins (b-carotene, thiamine, riboﬂavin, niacin, pyridoxine, folic acid and a-tocopherol), amino acids (alanine, arginine, aspartic
acid, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine,
tryptophan, tyrosine and valine), fatty acids (palmitic acid (16:0), palmitoleic acid (16:1), heptadecanoic acid (17:0), stearic acid
(18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), arachidic acid (20:0), eicosenoic acid (20:1) and behenic acid
(22:0)) and other compounds (ferulic acid, inositol, p-coumaric acid, phytic acid, rafﬁnose and trypsin inhibitor).
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The GMO Panel concludes that none of the compositional changes identiﬁed in maize MZHG0JG
with respect to its conventional counterpart and the commercial non-GM maize reference varieties
needs further assessment regarding food/feed safety.
3.4. Food/feed safety assessment21
3.4.1. Effects of processing
Based on the outcome of the comparative assessment (Section 3.3.7), processing of maize
MZHG0JG into food/feed products is not expected to result in products different from those of
commercial non-GM maize varieties.
3.4.2. Inﬂuence of temperature and pH on newly expressed proteins
Effects of temperature and pH on mEPSPS and PAT proteins have been previously evaluated by the
GMO Panel in the context of other applications (e.g. EFSA GMO Panel, 2007, 2009). Additional studies,
published in the literature or performed by the applicant, addressing effects of temperature and pH on
these proteins were provided in the context of this application. The outcome of these studies is
consistent with previous analogous studies assessed by the GMO Panel.
3.4.3. Toxicology
3.4.3.1. Testing of the newly expressed proteins
The two proteins newly expressed in maize MZHG0JG (mEPSPS and PAT) have been extensively
characterised (Section 3.2.3).
The mEPSPS and PAT proteins were previously assessed by the GMO Panel in the context of other
applications (i.e. EFSA GMO Panel, 2007, 2009) and no safety concerns for humans and animals were
identiﬁed. Updated bioinformatics analyses reveal no similarities of the mEPSPS and PAT proteins with
known toxins. The GMO Panel is not aware of any new information that would change the conclusion
that the mEPSPS and PAT proteins do not raise safety concerns.
Based on scientiﬁc knowledge, no synergistic or antagonistic interactions raising food/feed safety
concerns exist between the mEPSPS and PAT proteins.
Evidence provided by the applicant conﬁrms that E. coli-produced mEPSPS and PAT proteins from
bacterial recombinant systems are equivalent to the plant-produced ones.
a) In vitro degradation studies
Data on in vitro protein degradation of the mEPSPS and PAT proteins were previously evaluated by
the GMO Panel (i.e. EFSA GMO Panel, 2007, 2009). Additional data gathered by the applicant and
relevant publications give no indications of safety concerns, conﬁrming the outcome of former studies.
b) Acute oral toxicity testing
A bacterial mEPSPS and PAT protein was administrated at the dose of 2000 mg/kg body weight
(bw) to male and female Alpk:APfCD-1 mice and Crl:CD-1 mice, respectively. No adverse effects
related to the mEPSPS and PAT proteins are observed.
3.4.3.2. Testing of new constituents other than the newly expressed proteins
No new constituents other than newly expressed proteins have been identiﬁed in seed and forage
from maize MZHG0JG. Therefore, no further food/feed safety assessment of components other than
the newly expressed proteins is required.
3.4.3.3. Information on altered levels of food/feed constituents
No altered levels of food/feed constituents have been identiﬁed in seed and forage from maize
MZHG0JG. Therefore, no further food/feed safety assessment of components other than the newly
expressed proteins is required.
21 Dossier: Part II – Sections 1.3–1.6, 2–4 and 7; Additional information: 24/10/2017, 16/5/2018, 28/5/2018, 23/7/2018, 17/8/2018,
1/10/2018 and 15/10/2018.
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3.4.3.4. Testing of the whole genetically modiﬁed food/feed
Based on the outcome of the studies considered in the molecular characterisation and comparative
analysis, no substantial modiﬁcations in the composition of maize MZHG0JG, and no indication of
possible unintended effects relevant to food/feed safety have been identiﬁed. Therefore, animal
feeding studies with food/feed derived from maize MZHG0JG are not considered necessary by the
GMO Panel (EFSA GMO Panel, 2011a). In accordance with Regulation (EU) No 503/2013, the applicant
provided a 90-day oral repeated-dose toxicity study on whole food/feed from maize MZHG0JG in rats.
In addition, a 42-day broiler study with animals fed diets containing maize MZHG0JG material was
provided. These studies are evaluated by the GMO Panel.
90-day feeding study in rat
Pair-housed Han Wistar rats (RccHan:WIST) (10 per sex per group) were allocated to four groups
using a randomised complete block design with ﬁve replications per sex.
Groups were fed test or control diets containing 10% or 41.5% (w/w) ground grain from maize
MZHG0JG plants treated with the intended herbicides (test item) or from the conventional counterpart
(control material), respectively.
The study was adapted from OECD (1998), aligned with EFSA Scientiﬁc Committee (2011), and
complies with the principles of good laboratory practice (GLP) with some deviations not impacting the
study results and interpretation (i.e. test item stability, homogeneity and concentration), which are
detailed below.
Event-speciﬁc PCR analysis conﬁrms the presence of the event MZHG0JG in the GM grains and GM
diets and excludes the presence of the event in the respective controls. ELISA analyses also conﬁrm
the presence of event MZHG0JG only in the test diets. Both test item and control materials were
analysed for nutrients, mycotoxins and pesticides. Balanced diets were based on the CT1 diet prepared
by Special Diet Services Limited, with ground grain inclusion rate of 10% or 41.5% (w/w).
In accordance to product expiration standards declared by the diet manufacturer, the constituents
of the basal diets are considered stable for the duration of the treatment. However, the stability of the
test and control materials was not veriﬁed in this study. Diet preparation procedures and regular
evaluations of the mixing methods guarantee the homogeneity and the proper concentration of the
test or control substances in them.
Feed and water were provided ad libitum. Animals were checked twice daily for mortality and clinical
signs. Detailed physical examinations were conducted on all animals pretreatment and then weekly
during the dosing period. Individual body weights were recorded pretreatment and then weekly during
the dosing period and on the ﬁrst day of the scheduled necropsy. Feed consumption was determined
once during pretreatment and then weekly during the study. Ophthalmoscopy was recorded on all
animals pretreatment and at the end of the study (week 13). Detailed function observations (DFO) were
recorded on all animals at the end of the study (week 12). Clinical pathology (i.e. haematology, clinical
chemistry and coagulation, urine analyses) and necropsy examination with organs weighing were
conducted at the end of the treatment period on all animals. The animals were not fasted prior to blood
collection. Organs and tissues from all animals were collected and those from animals that consumed the
41.5% incorporation level test and control diets were subjected to a detailed histopathological
examination. Upon completion of the histopathologic assessment of all tissues, histopathology was
reviewed by a peer review pathologist.
In the ﬁrst analysis provided by the applicant, test and control diets were compared by pooling
data from diets at 10% inclusion rate (10% diets) and at 41.5% inclusion rate (41.5% diets).
However, the GMO Panel noted that the 10% and 41.5% diets had a different composition in terms of
ingredients (for both test and control), and therefore considers it inappropriate to pool data from two
qualitatively different diets groups in the analysis. For this reason, the applicant was requested to
analyse the data for the 10% and 41.5% diets separately. The GMO Panel bases its risk assessment on
the results of the latter analysis.
In the statistical analysis, for each of the two inclusion rates, rats consuming the test diet are
compared with those consuming the control diet. The cage is considered the experimental unit. For
continuous parameters, a multi-way analysis of variance (ANOVA) is conducted for the two sexes
combined (factors: treatment, sex, block-within-sex and sex-by-treatment interaction); if a signiﬁcant
sex-by-treatment interaction is identiﬁed, a two-way ANOVA (factors: treatment and block) is performed
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separately for males and females. The two-way ANOVA model is also used to analyse sex-speciﬁc organ
weights. Normality, homogeneity of variance and the presence of outliers were checked in a preliminary
analysis22 and a log transformation was applied in case of heterogeneity of variance. Outliers were
identiﬁed for eight parameters: for each of those, the ANOVA was run with and without outlier to check
if there were changes in the outcome of the tests.23
Sex-by-treatment interactions were observed for several endpoints. For these, gender speciﬁc
analyses were conducted, which revealed no statistically signiﬁcant differences.
All animals survived the treatment period. No test diet-related clinical signs and ophthalmoscopic
ﬁndings are observed.
No statistically signiﬁcant differences in mean body weights and feed consumption are observed
between animals fed the test and control 10%-diets or the test and control 41.5%-diets.
No statistically signiﬁcant differences in DFO parameters are observed between animals fed the test
and control 10%-diets or the test and control 41.5%-diets, with the exception of basic and ﬁne motor
activity tests between animals (across sex analysis, i.e. males and females analysed together) fed the
test and control 41.5%-diets. These differences are the only changes observed among all the DFO
parameters examined, occurring only at a single measurement time interval (the interval between 36
and 40 min) of a total of 13 time intervals analysed, without impacting on the overall score of the test;
therefore these changes are not considered to be test substance related.
No statistically signiﬁcant differences in haematological and coagulation parameters are observed
between animals fed the test and control 10%-diets or the test and control 41.5%-diets, with the
exception of mean red blood cell count (RBC) and haematocrit (Hct) between females fed the test and
control 10%-diets and mean cell haemoglobin concentration (MCHC) between animals (across sex
analysis) fed the test and control 10%-diets. The magnitude of the lower RBC count (~ 5%) and Hct
concentration (~ 4%) and the higher MCHC (~ 1%) in animals fed the test diet compared to control is
minimal and not considered to be toxicologically relevant.
Statistically signiﬁcant decreases are observed in mean globulin values (~ 6%) in females fed the
test 10%-diets and in mean alkaline phosphatase (ALP) activity (~ 13%) in animals (across sex
analysis) fed the test 10%-diets, compared the respective controls. The difference in mean globulin
values are minimal and not associated with other changes in related endpoints (e.g. A/G ratio and
total protein concentration) and therefore not considered to be toxicologically relevant. The isolated
decrease in ALP activities in the absence of other clinical or pathological signs is not considered to be
toxicologically relevant.
Statistically signiﬁcant decreases in mean lactate dehydrogenases (LDH) activity (~ 30%) in males
fed the test 41.5%-diets, compared controls are observed. The isolated decrease in LDH values in the
absence of other clinical or pathological signs is not considered to be toxicologically relevant.
Statistically signiﬁcant differences are observed for absolute and relative uterus weights (~ 40%) in
females fed the test and control 41.5%-diets and for absolute brain (~ 2% adjusted and non-adjusted)
and thyroid weights (~ 6% unadjusted only) between animals (across sex analysis) fed the test and
control 10%-diets. The magnitude of the differences observed in brain and thyroid weights is minimal,
the uterus weights in animals fed the control 41.5%-diets are lower than weights in other groups and
no test substance-related histological changes are noted in all three organs. Therefore, the GMO
Panel does not consider these changes as adverse effects.
No treatment-related gross lesions in all groups (10%- and 41.5%-diet groups) or microscopic
ﬁndings in the 41.5%-diet groups are noted in organs or tissues. Sporadic histopathological ﬁndings
are considered compatible with the spontaneous background pathology of rats of this strain and age.
The GMO Panel concludes that no maize MZHG0JG-related adverse effects are observed in this
study.
The GMO Panel notes that the applicant only tested one dose level with the full set of OECD
parameters. However, the dose tested is close to the highest possible without inducing nutritional
imbalance according to the current knowledge, and in accordance with the limit test dose as described
in OECD (1998). Therefore, this is not considered to affect the above conclusions.
22 Normality was checked by visual inspection of residual plots. Homogeneity of variance was checked both visually and with
Levene’s test.
23 Outliers were identiﬁed for: LUC at 10%, lymph at 41.5%, WBC at 41.5%, albumin/globulin ratio at 10% and 41.5%, AST at
10% and 41.5%, relative kidney at 10% and 41.5%, relative lung weight at 41.5%, relative testes weight at 10% and relative
uterus weight at 10%.
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42-day broiler study
A total of 600 (300 per sex) 1-day-old chicken broilers (Ross 708) were randomly allocated to ﬁve
dietary groups with 120 chicks per treatment (10 pens per treatment, half for each sex, 12 birds per
pen) and fed-balanced diets24 containing up to 59% maize MZHG0JG grain, from maize sprayed with
the intended herbicides (test item), or from the conventional counterpart (control diet) or one of the
three commercial non-GM maize reference varieties selected (reference diets). Diets (as crumbled
pellets or pellets) and water were offered ad libitum.
No statistically signiﬁcant difference between the group fed test and control diets are observed in
mortality (about 4%). Feed consumption and body weight in the test group are consistently higher
throughout the study compared to the control group, showing statistical signiﬁcance at some time
points. However, these ﬁndings are not associated to statistically signiﬁcant differences in the feed
conversion ratio and thus not considered adverse. Furthermore, no statistically signiﬁcant differences
are observed in carcass and absolute/relative tissue weight between the test and control groups, with
the exception of a lower relative mean breast weight in the test group.
The GMO Panel concludes that the administration of diets containing up to 59% maize MZHG0JG
grain to broilers does not cause adverse effects. Moreover, the measured performance endpoints are
similar between groups of animals fed-balanced diets containing maize MZHG0JG and the conventional
counterpart.
3.4.4. Allergenicity
The strategy to assess the potential risk of allergenicity focuses on the source of the recombinant
protein, on the potential of the newly expressed protein to induce sensitisation or to elicit allergic
reactions in already sensitised individuals, and on whether the genetic transformation may have
altered the allergenic properties of the modiﬁed plant.
3.4.4.1. Assessment of allergenicity of the newly expressed proteins
A weight-of-evidence approach is followed, taking into account all of the information obtained on
the newly expressed protein, as no single piece of information or experimental method yields sufﬁcient
evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA GMO Panel, 2010c, 2011a).
The mepsps and the pat genes originate from Z. mays and S. viridochromogenes, respectively,
which are not considered to be common allergenic sources.
Updated bioinformatic analyses of the amino acid sequences of the mEPSPS and PAT proteins,
using the criterion of 35% identity in a sliding window of 80 amino acids, reveal no signiﬁcant
similarities to known allergens.
The studies on resistance to degradation of the mEPSPS and PAT proteins by pepsin are described
in Section 3.4.3.1. No indications pointing to safety concerns are identiﬁed. The GMO Panel has
previously evaluated the safety of the mEPSPS and PAT proteins in the context of other applications
and no concerns on allergenicity were identiﬁed (i.e. EFSA GMO Panel, 2007, 2009). The GMO Panel is
not aware of any new information that would change this conclusion.
There is no information available on the structure or function of the newly expressed mEPSPS and
PAT proteins that would suggest an adjuvant effect of the individual proteins or their simultaneous
presence in maize MZHG0JG, resulting in or enhancing an eventual speciﬁc immunoglobulin E response
to a bystander protein.
In the context of the present application, the GMO Panel considers that there are no indications
that the newly expressed mEPSPS and PAT proteins in maize MZHG0JG may be allergenic.
3.4.4.2. Assessment of allergenicity of the whole GM plant
The GMO Panel regularly reviews the available publications on food allergy to maize. However, to
date, maize is not considered to be a common allergenic food (OECD, 2002).25 Therefore, the GMO
Panel does not request experimental data to analyse the allergen repertoire of GM maize.
24 Starter (0–7 days), grower (8–21 days) and ﬁnisher (22–42 days) diets.
25 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and No 1925/2006 of the European Parliament and of
the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
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The applicant provided spontaneous information where lipid transfer protein (LTP, a known allergen
in maize) levels in maize MZHG0JG were compared to those in the conventional counterpart and
commercial non-GM maize reference varieties. No changes in LTP levels raising concern are identiﬁed
by the GMO Panel.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins, the GMO Panel ﬁnds no
reason of concern regarding the allergenicity of food/feed derived from maize MZHG0JG with respect
to that derived from its conventional counterpart.
3.4.5. Dietary intake assessment of endogenous and new constituents
3.4.5.1. Nutritional assessment of endogenous constituents
The intended traits of maize MZHG0JG are herbicide tolerance, with no intention to alter nutritional
parameters. Comparison of the seed and forage composition of maize MZHG0JG with the conventional
counterpart and the commercial non-GM maize reference varieties does not identify differences that
would require a nutritional assessment as regards food/feed (see Section 3.3.6). From these data, the
GMO Panel concludes that the nutritional impact of food/feed derived from maize MZHG0JG is
expected to be similar to that from the conventional counterpart and commercial non-GM maize
reference varieties.
3.4.5.2. Dietary exposure to new constituents
In line with Regulation (EU) No 503/2013, the applicant provided dietary exposure estimates to
mEPSPS and PAT proteins which are newly expressed present in maize MZHG0JG.
Human dietary exposure
Chronic and acute dietary exposure estimates for mEPSPS and PAT proteins newly expressed in
maize MZHG0JG were provided by the applicant. Dietary exposure is estimated across different
European countries on different population groups: young population group (infants, toddlers, other
children), adult population group (adolescents, adults, elderly and very elderly) and special population
groups (pregnant and lactating women) (see below Table 4).
For the purpose of estimating dietary exposure, the mean protein expression levels in mature
grains (from senescent plants) treated with the intended herbicides from four ﬁeld trial locations in the
USA were used by the applicant.25 A mean value of 31.88 lg/g (fresh weight, n = 20) is reported for
mEPSPS; all samples for the PAT protein are below the limit of detection (LOD) and this value
(0.025 lg/g fresh weight) is used as worst-case scenario. Since the concentrations of the mEPSPS and
PAT proteins were not analysed in processed foods, their concentration in these commodities is
estimated using the ratio between the total protein contents of processed foods and maize grains. The
assumption is that no losses of the newly expressed proteins occur during processing.
Regarding consumption data, a conservative scenario with 100% replacement of conventional
maize is considered, as no speciﬁc data are available on the consumption of commodities containing
maize MZHG0JG. Maize oil is excluded from the assessment because proteins are not expected to be
present in oil. Consumption data of the relevant commodities (e.g. corn bread, corn ﬂakes, corn milling
products, cornmeal porridge, corn grain, corn snacks, sweet corn, popcorn, etc.) were retrieved by the
applicant from the available summary statistics of the EFSA Comprehensive European Food
Consumption Database (accessed in April 2018).26 EFSA’s consumption database contains information
on food consumption data at individual level from the most recent national dietary surveys in different
EU Member States (EFSA, 2011; Huybrechts et al., 2011; Merten et al., 2011), and is regularly
updated with new consumption data collected in the context of the EU Menu project.27
Acute dietary exposure in high consumers within each dietary survey and age class is estimated by
summing the exposure derived from the 95th percentile consumption for the dominant food
commodity28 among consumers only and those exposures derived from the mean consumption of the
remaining food categories in the total population (EFSA, 2015). Among the young population, the
highest acute exposure is estimated in other children (3–10 years old) following the consumption of
popcorn (612.7 lg/kg bw per day and 0.48 lg/kg bw per day for mEPSPS and PAT, respectively). In
26 https://www.efsa.europa.eu/en/applications/gmo/tools
27 https://www.efsa.europa.eu/en/efsajournal/pub/3944
28 Dominant food commodity refers to the food leading to the highest exposure among all consumed foods.
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adults (18–65 years old), the consumption of maize-popped cereals leads to the highest acute exposure
estimates, 262.8 lg/kg bw per day and 0.21 lg/kg bw per day for mEPSPS and PAT, respectively.
Chronic dietary exposure in high consumers is estimated using only dietary surveys representing
long-term consumption (at least with 2 days). Among the young population group, the highest chronic
exposure is estimated in toddlers (1–3 years old) with corn chips as the main average contributor
(56.1 lg/kg bw per day and 0.044 lg/kg bw per day for mEPSPS and PAT, respectively). In the adult
population group, the highest chronic exposure is estimated for elderly and very elderly (> 65 years)
with 22.1 lg/kg bw per day and 0.017 lg/kg bw per day for mEPSPS and PAT, respectively, with
cornmeal porridge as the main average contributor.
Animal dietary exposure
Daily dietary exposure (DDE) to the mEPSPS and PAT proteins newly expressed in maize MZHG0JG
was provided by the applicant across different livestock animal species (e.g. poultry, swine, cattle and
sheep) based on EU estimates issued by OECD (2013) for animal body weight, daily feed intake and
the inclusion rates (percentage) of maize grains and maize grain by-products (i.e. milled by products,
hominy meal, gluten feed and gluten meal) in animal diets.
A conservative scenario with 100% replacement of the conventional maize (maize grains, milled by
products, hominy meal, gluten feed and gluten meal) is considered.
The levels of mEPSPS (42.79 lg/g fresh weight) and PAT (LOD = 0.025 lg/g fresh weight) proteins
in grains from maize MZHG0JG25 are used as occurrence data and to estimate levels (as fed) of these
proteins in maize grain by-products,29 based on the protein content in feed fractions relative to maize
grain and assuming that no protein is lost during the processing. The mEPSPS and PAT levels are in
line with mean levels (n = 20) reported for grains (R6) treated with the intended herbicides (see
Section 3.2.4). Fresh to dry weight conversion for maize grains and by-products is based on the dry
matter content as reported in OECD (2013) (88% for grain and hominy, 85% for milled by-products
and 40% for gluten feed and gluten meal); dry matter content (90%) for gluten meal is also
considered.
Estimated DDE to mEPSPS was calculated by the applicant as the sum of the estimated intake of
grain and gluten meal (by-product containing the highest amount of mEPSPS and PAT), ranging from
2.36 mg/kg in breeding swine to 9.32 mg/kg in lambs using gluten meal 40% dry matter (DM) and
1.49 mg/kg in breeding swine to 4.49 mg/kg in lambs using gluten meal 90% DM.
Estimated DDE to PAT was calculated by the applicant as the sum of the estimated intake of grain
and gluten meal (by-product containing the highest amount of mEPSPS and PAT), ranging from
0.0013 mg/kg in breeding swine to 0.0054 mg/kg in lambs using gluten meal 40% DM and
0.00087 mg/kg in breeding swine to 0.00262 mg/kg in lambs using gluten meal 90% DM.
Table 4: Dietary exposure (chronic and acute) to mEPSPS and PAT proteins in high consumers (lg/
kg bw per day) estimated across European dietary surveys and different age classes
Age class
Dietary exposure high consumers (lg/kg bw per day)
mEPSPS PAT
Chronic Acute Chronic Acute
Range Range
Infants 9.1–43.8 88.1–136.9 0.007–0.034 0.07–0.10
Toddlers 4.1–56.1 46.4–448.8 0.003–0.044 0.04–0.35
Other children 10.3–48.2 60.6–612.7 0.008–0.038 0.05–0.48
Adolescents 4.5–27.9 42.9–426.0 0.004–0.022 0.03–0.33
Adults 0.4–15.1 26.8–262.8 0.001–0.012 0.02–0.21
Elderly and very elderly 0.5-22.2 7.0–252.7 0.001–0.017 0.01–0.20
Special population(a) 17.4–20.3 73.7–146.9 0.014–0.016 0.06–0.12
bw: body weight.
(a): Pregnant women and lactating women.
29 Calculated to be 1.06, 0.9, 2.13 and 6.38-folds than that in grain in hominy, milled by-products, gluten feed and gluten meal,
respectively.
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The GMO Panel estimates DDE to the mEPSPS and PAT proteins across different livestock animal
species (beef and dairy cows, lamb and breeding swine) based on default values provided for the EU
by OECD (2013) for animal body weight, daily feed intake and inclusion rates (percentages) of ﬁeld
maize forage/silage in animal diets (information that was not provided by the applicant). A
conservative scenario with 100% replacement of conventional maize (forage) by the GM maize is
considered. Mean values of 298 lg/g and 0.41 lg/g25 (dry weight, n = 20) in herbicide-treated maize
whole plant (including the root ball, R6) are used as occurrence data for mEPSPS and PAT respectively.
LOQ = 0.063 lg/g (dry weight) and LOD = 0.025 lg/g (dry weight) were considered in the calculation
of the PAT mean values as a worst-case scenario in whole plant (R6). Estimated DDEs to the mEPSPS
protein, based on the consumption of GM maize forage, is 5.7 mg/kg bw in beef, 6.9 mg/kg bw in
dairy cow, 3.8 mg/kg bw in lamb and 1.4 mg/kg bw in breeding swine.
Estimated DDEs to the PAT protein, based on the consumption of GM maize forage, is 0.008 mg/kg bw
in beef, 0.009 mg/kg bw in dairy cow, 0.005 mg/kg bw in lamb and 0.001 mg/kg bw in breeding swine.
3.4.6. Post-market monitoring of GM food/feed
The GMO Panel concludes that maize MZHG0JG is nutritionally equivalent to and as safe as the
conventional counterpart and commercial non-GM maize reference varieties tested. No post-market
monitoring (EFSA GMO Panel, 2011a) of food/feed is considered necessary.
3.4.7. Conclusion on the food/feed safety assessment
The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the
mEPSPS and PAT proteins as expressed in maize MZHG0JG, and ﬁnds no evidence that the genetic
modiﬁcation would change the overall allergenicity of maize MZHG0JG. The nutritional impact of food/
feed derived from maize MZHG0JG is expected to be the same as that of food/feed derived from the
conventional counterpart and commercial non-GM maize reference varieties. The GMO Panel concludes
that maize MZHG0JG is nutritionally equivalent to and as safe as the conventional counterpart and
non-GM maize reference varieties tested, and no post-market monitoring of food/feed is considered
necessary.
3.5. Environmental risk assessment and monitoring plan30
3.5.1. Environmental risk assessment
Considering the scope of the application EFSA-GMO-DE-2016-133, which excludes cultivation, the
environmental risk assessment (ERA) of maize MZHG0JG mainly takes into account: (1) the exposure
of microorganisms to recombinant DNA in the gastrointestinal tract of animals fed GM material and of
microorganisms present in environments exposed to faecal material of these animals (manure and
faeces); and (2) the accidental release into the environment of viable maize MZHG0JG grains during
transportation and/or processing (EFSA GMO Panel, 2010a).
3.5.1.1. Persistence and invasiveness of the GM plant
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, absence of a dormancy phase and susceptibility to plant
pathogens, herbivores and cold climate conditions (OECD, 2003). Field observations indicate that maize
grains may survive and overwinter in some EU regions, resulting in volunteers in subsequent crops (e.g.
Gruber et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers have been
shown to grow weakly and ﬂower asynchronously with the maize crop (Palaudelmas et al., 2009). Thus,
the establishment and survival of feral and volunteer maize in the EU is currently limited and transient.
It is unlikely that the intended traits of maize MZHG0JG and the observed reduction in early stand
count (see Section 3.3.4) will provide a selective advantage to maize plants, except when they are
exposed to glyphosate- and/or glufosinate-ammonium-containing herbicides. However, this ﬁtness
advantage will not allow maize MZHG0JG to overcome other biological and abiotic factors (described
above) limiting plant’s persistence and invasiveness. Therefore, the presence of the intended traits and
30 Dossier: Part II – Sections 5, 6 and 7; Additional information: 15/5/2018.
Assessment of maize MZHG0JG
www.efsa.europa.eu/efsajournal 20 EFSA Journal 2018;16(11):5469
the observed difference in early stand count will not affect the persistence and invasiveness of the GM
plant.
In conclusion, it is very unlikely that maize MZHG0JG will differ from conventional maize hybrid
varieties in its ability to survive until subsequent seasons, or to establish occasional feral plants under
European environmental conditions in case of accidental release into the environment of viable maize
MZHG0JG grains.
3.5.1.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene ﬂow via cross-pollination from feral
plants originating from spilled grains.
Plant-to-microorganism gene transfer
Genomic DNA can be a component of food/feed products derived from maize. It is well
documented that such DNA becomes substantially degraded during processing and digestion in the
human or animal gastrointestinal tract. However, bacteria in the digestive tract of humans and
domesticated animals, and in other environments may be exposed to fragments of DNA, including the
recombinant fraction of such DNA.
Current scientiﬁc knowledge of recombination processes in bacteria suggests that horizontal
transfer of non-mobile, chromosomally-located DNA fragments between unrelated organisms (such as
from plants to bacteria) is not likely to occur at detectable frequencies under natural conditions (for
further details, see EFSA, 2009).
The only mechanism known to facilitate horizontal transfer of non-mobile, chromosomal DNA
fragments to bacterial genomes is homologous recombination. This requires the presence of at least
two stretches of DNA sequences that are similar in the recombining DNA molecules. In the case of
sequence identity with the transgene itself, recombination would result in gene replacement. In the
case of identity with two or more regions ﬂanking recombinant DNA, recombination could result in the
insertion of additional DNA sequences in bacteria and thus confer the potential for new properties.
The bioinformatic analysis of the event MZHG0JG revealed only a single element, the nos
terminator from A. tumefaciens, which could provide sufﬁcient length and sequence identity to
facilitate homologous recombination. However, the T-nos terminator by itself cannot support double
homologous recombination.
In summary, there is no indication for an increased likelihood of horizontal transfer of DNA from
maize MZHG0JG to bacteria. Given the nature of the recombinant DNA, the GMO Panel identiﬁes no
safety concern linked to an unlikely but theoretically possible HGT.
Plant-to-plant gene transfer
The potential for occasional feral GM maize MZHG0JG plants originating from grain import spills to
transfer recombinant DNA to sexually compatible plants and the environmental consequences of this
transfer were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
ﬂowering and environmental conditions favouring cross-pollination.
Maize is an annual predominantly cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize
outside cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA,
2016; Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and
weedy Zea species, such as teosintes and/or maize-teosinte hybrids, occurring in cultivated areas
(EFSA, 2016; Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.5.1.1). Therefore, likelihood/frequency of cross-pollination between occasional
feral GM maize plants resulting from grain spillage, and weedy or cultivated Zea plants is considered
extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the opinion that
environmental effects as a consequence of the spread of genes from occasional feral GM maize plants
in Europe will not differ from that of conventional maize varieties for the reasons given in
Section 3.5.1.1, even if exposed to the intended herbicides.
Assessment of maize MZHG0JG
www.efsa.europa.eu/efsajournal 21 EFSA Journal 2018;16(11):5469
3.5.1.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-DE-2016-133 (no cultivation) and thus the absence of
target organisms into account, potential interactions of occasional feral maize MZHG0JG plants arising
from grain import spills with target organisms are not considered a relevant issue by the GMO Panel.
3.5.1.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled maize MZHG0JG grains is limited and because ingested proteins
are degraded before entering the environment through faecal material of animals fed GM maize,
potential interactions of maize MZHG0JG with non-target organisms are not considered by the GMO
Panel to raise any environmental safety concern.
3.5.1.5. Interactions with the abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled grains or occasional feral maize MZHG0JG plants
arising from grain import spills is limited and because most proteins are degraded before entering the
environment through faecal material of animals fed GM maize, potential interactions with the abiotic
environment and biogeochemical cycles are not considered by the GMO Panel to raise any
environmental safety concern.
3.5.2. Post-market environmental monitoring
The objectives of a post-market environmental monitoring (PMEM) plan, according to Annex VII of
Directive 2001/18/EC, are to: (1) conﬁrm that any assumption regarding the occurrence and impact of
potential adverse effects of the GMO, or its use, in the ERA are correct; and (2) identify the occurrence
of adverse effects of the GMO, or its use, on human health or the environment that were not
anticipated in the ERA.
Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA does not identify potential adverse environmental effects from the maize MZHG0JG, no
case-speciﬁc monitoring is required.
The PMEM plan proposed by the applicant for maize MZHG0JG includes: (1) the description of an
approach involving operators (federations involved in maize import and processing), reporting to the
applicant, via a centralised system, any observed adverse effect(s) of GMOs on human health and
the environment; (2) a coordinating system newly established by EuropaBio for the collection of the
information recorded by the various operators; and (3) the review of relevant scientiﬁc publications
retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The applicant proposes to
submit a PMEM report on an annual basis and a ﬁnal report at the end of the authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of maize MZHG0JG. The GMO Panel agrees with the reporting intervals
proposed by the applicant in its PMEM plan.
In the context of PMEM, the applicant should improve future literature searches according to the
GMO Panel recommendations given in Section 3.1.
3.5.3. Conclusion on the environmental risk assessment and monitoring plan
The GMO Panel concludes that it is unlikely that maize MZHG0JG would differ from conventional
maize varieties in its ability to persist under EU environmental conditions. Considering the scope of
application EFSA-GMO-DE-2016-133, interactions of occasional feral maize MZHG0JG plants with the
biotic and abiotic environment are not considered to be relevant issues. The analysis of HGT from
maize MZHG0JG to bacteria does not indicate a safety concern. Therefore, considering the introduced
traits, the outcome of the comparative analysis, the routes and levels of exposure, the GMO
Panel concludes that maize MZHG0JG would not raise safety concerns in the event of accidental
release of viable GM maize grains into the environment.
The scope of the PMEM plan provided by the applicant and the reporting intervals are in line with
the intended uses of maize MZHG0JG.
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4. Conclusions
The GMO Panel was asked to carry out a scientiﬁc assessment of maize MZHG0JG for import,
processing and food and feed uses in accordance with Regulation (EC) No 1829/2003.
The molecular characterisation data establish that maize MZHG0JG contains a single insert
consisting of one copy of the mepsps and pat expression cassettes. Bioinformatics analyses of the
sequences encoding the newly expressed proteins and other ORFs present within the insert or
spanning the junctions between the insert and genomic DNA do not indicate signiﬁcant similarities to
toxins and allergens. The stability of the inserted DNA and introduced trait is conﬁrmed over several
generations. The methodology used to quantify the levels of the mEPSPS and PAT proteins is
considered adequate. The protein characterisation data comparing the structural, biochemical and
functional properties of plant- and microbe-derived mEPSPS and PAT proteins indicate that these
proteins are equivalent, and the microbe-derived protein can be used in safety studies.
None of the identiﬁed differences in the agronomic/phenotypic and compositional characteristics
tested between maize MZHG0JG and its conventional counterpart needs further assessment, with the
exception of the early stand count (pre-thinning) whose environmental impact is assessed.
The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the
mEPSPS and PAT proteins as expressed in maize MZHG0JG, and ﬁnds no evidence that the genetic
modiﬁcation would change the overall allergenicity of maize MZHG0JG. The nutritional impact of food/
feed derived from maize MZHG0JG is expected to be the same as that of food/feed derived from the
conventional counterpart and commercial non-GM maize reference varieties. The GMO Panel concludes
that maize MZHG0JG is nutritionally equivalent to and as safe as the conventional counterpart and
non-GM maize reference varieties tested, and no post-market monitoring of food/feed is considered
necessary.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from maize MZHG0JG into the environment. The PMEM plan and
reporting intervals are in line with the intended uses of maize MZHG0JG.
Based on the relevant publications identiﬁed through the literature searches, the GMO Panel does
not identify any safety issues pertaining to the intended uses of maize MZHG0JG. In the context of
PMEM, the applicant should improve future literature searches according to the GMO
Panel recommendations given in this scientiﬁc opinion.
In conclusion, the GMO Panel considers that maize MZHG0JG, as described in this application, is as
safe as its conventional counterpart and the tested non-GM maize reference varieties with respect to
potential effects on human and animal health and the environment.
Documentation provided to EFSA
1) Application EFSA-GMO-DE-2016-133 received from the Competent Authority of Germany in
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Regulation (EC) No 1829/2003, 27 September 2016.
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5) Request for supplementary information to the applicant, 7 July 2017.
6) Receipt of supplementary information from the applicant, 24 July 2017.
7) Request for supplementary information to the applicant, 31 July 2017.
8) Receipt of supplementary information from the applicant, 24 October 2017.
9) Receipt of supplementary information from the applicant, 3 November 2017.
10) Request for supplementary information to the applicant, 18 December 2017.
11) Receipt of supplementary information from the applicant, 15 February 2018.
12) Request for supplementary information to the applicant, 16 February 2018.
13) Request for supplementary information to the applicant, 8 March 2018.
14) Request for supplementary information to the applicant, 12 April 2018.
15) Request for supplementary information to the applicant, 17 April 2018.
16) Receipt of supplementary information from the applicant, 14 May 2018.
17) Receipt of supplementary information from the applicant, 15 May 2018.
18) Receipt of supplementary information from the applicant, 16 May 2018.
19) Receipt of supplementary information from the applicant, 28 May 2018.
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20) Request for supplementary information to the applicant, 6 June 2018.
21) Request for supplementary information to the applicant, 3 July 2018.
22) Receipt of supplementary information from the applicant, 16 July 2018.
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References
Codex Alimentarius, 2009. Foods derived from modern biotechnology. Codex Alimentarius Commission, Joint FAO/
WHO Food Standards Programme, Rome. Available online: http://www.fao.org/docrep/011/a1554e/a1554e00.htm
Eastham K and Sweet J, 2002. Genetically modiﬁed organisms (GMOs): The signiﬁcance of gene ﬂow through
pollen transfer. Environmental Issue Report No 28. European Environment Agency, Copenhagen, Denmark.
Available online: http://www.eea.europa.eu/publications/environmental_issue_report_2002_28
EFSA (European Food Safety Authority), 2009. Statement of EFSA on the consolidated presentation of the joint
Scientiﬁc Opinion of the GMO and BIOHAZ Panels on the “Use of Antibiotic Resistance Genes as Marker Genes
in Genetically Modiﬁed Plants” and the Scientiﬁc Opinion of the GMO Panel on “Consequences of the Opinion
on the Use of Antibiotic Resistance Genes as Marker Genes in Genetically Modiﬁed Plants on Previous EFSA
Assessments of Individual GM Plants”. EFSA Journal 2009;8(6):1108, 107 pp. https://doi.org/10.2903/j.efsa.
2009.1108
EFSA (European Food Safety Authority), 2010. Application of systematic review methodology to food and feed safety
assessments to support decision making. EFSA Journal 2010;8(6):1637, 90 pp. https://doi.org/10.2903/j.efsa.
2010.1637
EFSA (European Food Safety Authority), 2014. Explanatory statement for the applicability of the Guidance of the
EFSA Scientiﬁc Committee on conducting repeated-dose 90-day oral toxicity study in rodents on whole food/feed
for GMO risk assessment. EFSA Journal 2014;12(10):3871, 25 pp. https://doi.org/10.2903/j.efsa.2014.3871
EFSA (European Food Safety Authority), 2015. Use of EFSA Comprehensive European Food Consumption
Database for estimating dietary exposure to genetically modiﬁed foods. EFSA Journal 2015;13(2):4034,
11 pp. https://doi.org/10.2903/j.efsa.2015.4034
EFSA (European Food Safety Authority), 2016. Relevance of new scientiﬁc evidence on the occurrence of teosinte
in maize ﬁelds in Spain and France for previous environmental risk assessment conclusions and risk
management recommendations on the cultivation of maize events MON810, Bt11, 1507 and GA21. EFSA
Supporting Publication 2016;EN-1094:1–13. https://doi.org/10.2903/sp.efsa.2016.EN-1094
EFSA(European Food Safety Authority), 2011. Evaluation of the FoodEx, the food classiﬁcation system applied to
the development of the EFSA Comprehensive European Food Consumption Database. EFSA Journal 2011;9
(3):1970, 27 pp. https://doi.org/10.2903/j.efsa.2011.1970
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2007. Opinion of the Scientiﬁc Panel on
Genetically Modiﬁed Organisms on applications (references EFSA-GMO-UK-2005-19 and EFSA-GMO-RX-GA21)
for the placing on the market of glyphosate-tolerant genetically modiﬁed maize GA21, for food and feed uses,
import and processing and for renewal of the authorisation of maize GA21 as existing product, both under
Regulation (EC) No 1829/2003 from Syngenta Seeds S.A.S. on behalf of Syngenta Crop Protection AG. EFSA
Journal 2007;541:1–25. https://doi.org/10.2903/j.efsa.2007.541
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2009. Scientiﬁc opinion of the Scientiﬁc
Panel on Genetically Modiﬁed Organisms on an application (Reference EFSA-GMO-RX-Bt11) for renewal of the
authorisation of existing products produced from insect-resistant genetically modiﬁed maize Bt11, under
Regulation (EC) No 1829/2003 from Syngenta. EFSA Journal 2009;977:1–13. https://doi.org/10.2903/j.efsa.
2009.977
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2010a. Guidance on the environmental risk
assessment of genetically modiﬁed plants. EFSA Journal 2010;8(11):1879, 111 pp. https://doi.org/10.2903/j.
efsa.2010.1879
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2010b. Statistical considerations for the safety
evaluation of GMOs. EFSA Journal 2010;8(1):1250, 59 pp. https://doi.org/10.2903/j.efsa.2010.1250
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2010c. Scientiﬁc Opinion on the assessment of
allergenicity of GM plants and microorganisms and derived food and feed. EFSA Journal 2010;8(7):1700,
168 pp. https://doi.org/10.2903/j.efsa.2010.1700
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2011a. Guidance for risk assessment of food
and feed from genetically modiﬁed plants. EFSA Journal 2011;9(5):2150, 37 pp. https://doi.org/10.2903/j.efsa.
2011.2150
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2011b. Guidance on the post-market
environmental monitoring (PMEM) of genetically modiﬁed plants. EFSA Journal 2011;9(8):2316, 40 pp.
https://doi.org/10.2903/j.efsa.2011.2316
Assessment of maize MZHG0JG
www.efsa.europa.eu/efsajournal 24 EFSA Journal 2018;16(11):5469
EFSA GMO Panel (EFSA Panel on Genetically Modiﬁed Organisms), 2015. Guidance on the agronomic and
phenotypic characterisation of genetically modiﬁed plants. EFSA Journal 2015;13(6):4128, 44 pp. https://doi.
org/10.2903/j.efsa.2015.4128
EFSA Scientiﬁc Committee, 2011. EFSA guidance on conducting repeated-dose 90-day oral toxicity study in
rodents on whole food/feed. EFSA Journal 2011;9(12):2438, 21 pp. https://doi.org/10.2903/j.efsa.2011.2438
EFSA (European Food Safety Authority), Devos Y, Guajardo IM, Glanville J and Waigmann E, 2017a. Explanatory
note on literature searching conducted in the context of GMO applications for (renewed) market authorisation
and annual post-market environmental monitoring reports on GMOs authorised in the EU market. EFSA
supporting publications 2017;14(4):EN-1207, 48 pp. https://doi.org/10.2903/sp.efsa.2017.EN-1207
EFSA (European Food Safety Authority), Gennaro A, Gomes A, Herman L, Nogue F, Papadopoulou N and Tebbe C,
2017b. Technical report on the explanatory note on DNA sequence similarity searches in the context of the
assessment of horizontal gene transfer from plants to microorganisms. EFSA supporting publications 2017;14
(7):EN-1273, 11 pp. https://doi.org/10.2903/sp.efsa.2017.en-1273
Gruber S, Colbach N, Barbottin A and Pekrun C, 2008. Post-harvest gene escape and approaches for minimizing it.
CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources, 3, 1–17.
Huybrechts I, Sioen I, Boon PE, Ruprich J, Lafay L, Turrini A, Amiano P, Hirvonen T, De Neve M, Arcella D,
Moschandreas J, Westerlund A, Ribas-Barba L, Hilbig A, Papoutsou S, Christensen T, Oltarzewski M, Virtanen S,
Rehurkova I, Azpiri M, Sette S, Kersting M, Walkiewicz A, SerraMajem L, Volatier JL, Trolle E, Tornaritis M, Busk L,
Kafatos A, Fabiansson S, De Henauw S and Van Klaveren J, 2011. Dietary exposure assessments for children in
Europe (the EXPOCHI project): rationale, methods and design. Archives of Public Health, 69, 4.
Lecoq E, Holt K, Janssens J, Legris G, Pleysier A, Tinland B and Wandelt C, 2007. General surveillance: roles and
responsibilities the industry view. Journal of Consumer Protection and Food Safety, 2, 25–28.
Merten C, Ferrari P, Bakker M, Boss A, Hearty A, Leclercq C, Lindtner O, Tlustos C, Verger P, Volatier JL and Arcella
D, 2011. Methodological characteristics of the national dietary surveys carried out in the European Union as
included in the European Food Safety Authority (EFSA) Comprehensive European Food Consumption Database.
Food Additives & Contaminants. Part A, 28, 975–995.
Moerschell RP, Hosokawa Y, Tsunasawa S and Sherman F, 1990. The speciﬁcities of yeast methionine
aminopeptidase and acetylation of amino-terminal methionine in vivo. Processing of altered iso-1-cytochromes
c created by oligonucleotide transformation. Journal of Biological Chemistry, 265, 19638–19643.
OECD (Organisation for Economic Co-operation and Development), 1998. Test No. 408: Repeated Dose 90-Day
Oral Toxicity Study in Rodents, OECD Publishing, Paris.
OECD (Organisation for Economic Co-operation and Development), 2002. Consensus Document on compositional
considerations for new varieties of maize (Zea mays): key food and feed nutrients, anti-nutrients and secondary
plant metabolites. Series on the Safety of Novel Food and Feeds (ENV/JM/MONO(2002)25), No 6, 1–42.
OECD (Organisation for Economic Co-operation and Development), 2003. Consensus Document on the biology of
Zea mays subsp. Mays (Maize). Series on Harmonisation of Regulatory Oversight in Biotechnology (ENV/JM/
MONO(2003)11), No 27, 1–49.
OECD (Organisation for Economic Co-operation and Development), 2013. Guidance document on residues in
livestock. Series on Pesticides No. 73. ENV/JM/MONO(2013)8.
Palaudelmas M, Pe~nas G, Mele E, Serra J, Salvia J, Pla M, Nadal A and Messeguer J, 2009. Effect of volunteers on
maize gene ﬂow. Transgenic Research, 18, 583–594.
Pascher K, 2016. Spread of volunteer and feral maize plants in Central Europe: recent data from Austria.
Environmental Sciences Europe, 28, 30. https://doi.org/10.1186/s12302-016-0098-1
Sys C, Van Ranst E, Debaveye J and Beernaert F, 1993. Land evaluation, Part III: Crop requirements. Agricultural
Publication N°7, G.A.D.C., Brussels, Belgium, pp 191.
Trtikova M, Lohn A, Binimelis R, Chapela I, Oehen B, Zemp N, Widmer A and Hilbeck A, 2017. Teosinte in Europe –
searching for the origin of a novel weed. Scientiﬁc Reports, 7, 1560. https://doi.org/10.1038/s41598-017-01478-w
Windels P, Alcalde E, Lecoq E, Legris G, Pleysier A, Tinland B and Wandelt C, 2008. General surveillance for import
and processing: the EuropaBio approach. Journal of Consumer Protection and Food Safety, 3, 14–16.
Abbreviations
ADF acid detergent ﬁbre
ALP alkaline phosphatase
ANOVA analysis of variance
bp base pair
bw body weight
CTP chloroplast transit peptide
CRM comparative relative maturity
DDE daily dietary exposure
DFO detailed function observation
DM dry matter
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ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
FAO Food and Agricultural Organisation of the United Nations
GLP good laboratory practice
GM genetically modiﬁed
GMO genetically modiﬁed organism
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
Hct haematocrit
HGT horizontal gene transfer
HR homologous recombination
LDH lactate dehydrogenases
LOD limit of detection
LTP lipid transfer protein
MCHC mean cell haemoglobin concentration
MS mass spectrometry
NDF neutral detergent ﬁbre
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PAT phosphinothricin acetyltransferase
PCR polymerase chain reaction
PMEM post-market environmental monitoring
RBC blood cell count
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
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